The Oxycodone Hydrochloride Market Size is valued at USD 412.4 Mn in 2023 and is predicted to reach USD 572.8 Mn by the year 2031 at a 4.33% CAGR during the forecast period for 2024-2031.
Oxycodone hydrochloride is a prescribed opioid analgesic utilized for the management of moderate to severe pain, particularly when alternative analgesics, such as non-opioid medicines, prove inadequate. It functions by attaching to opioid receptors in the brain and spinal cord, modifying the experience of pain and the emotional response to it.
The rising incidence of chronic pain disorders is driving a notable expansion in the oxycodone hydrochloride industry. Many people throughout the world suffer from persistent discomfort, which is frequently brought on by serious medical conditions, including arthritis, cancer, and muscular problems. There is an increasing need for efficient pain management options as populations survive harder and greater numbers suffer from these crippling illnesses. Oxycodone hydrochloride is a crucial treatment choice for delivering perpetual pain reduction, especially in its extended-release development.
However, the growing popularity of the worldwide oxycodone hydrochloride sector is expected to face significant obstacles in the years ahead due to stringent government regulations pertaining to the prescriptions and usage of the medication for individuals seeking pain treatment. A number of adverse consequences brought on by using these medications may make the industry's expansion even more difficult. The COVID-19 epidemic has affected the market, leading to the shutdown of multiple firms to prevent viral transmission among employees. This could impede the industry's growth.
Competitive Landscape
Some Major Key Players In The Oxycodone Hydrochloride Market:
- Eli Lilly and Company
- Gilead Sciences, Inc.
- Manus Aktteva Biopharma LLP
- Arevipharma GmbH
- Saneca Pharma a.s.
- Cipla Ltd.
- Noramco, Inc.
- MacFarlan Smith
- Teva Pharmaceutical Industries Ltd.
- Taj Pharma
- Chattem Chemicals Inc
- Mayne Pharma Group Ltd.
- Dr Reddy's Laboratories Limited
- Siegfried
- Rhodes Pharmaceuticals L.P.
- Mallinckrodt Pharmaceuticals
- Johnson & Johnson
- Bristol-Myers Squibb Company
- Sun Pharmaceutical Industries Limited
- Lupin Limited
- Protega Pharmaceuticals
- Sanofi S.A.
- Other Market Players
Market Segmentation:
The oxycodone hydrochloride market is segmented based on type, route of administration, and distribution channel. Based on type, the market includes into controlled-release and immediate-release. The route of administration segment comprises oral and parenteral. By distribution channel, the market consists of hospital pharmacies, retail pharmacies, and online pharmacies.
Based On The Type, The Controlled-Release Oxycodone Hydrochloride Market Segment Is Accounted As A Prominent Contributor To The Oxycodone Hydrochloride Market
The controlled-release oxycodone hydrochloride market will hold a major global market share, because of its capacity to regulate the absorption of oxycodone hydrochloride medications, which are used to treat individuals' extreme to significant pain. Furthermore, because of the increasing harm, distraction, and overuse of oxycodone hydrochloride, the medication's-controlled release is supported. Also, the growing demand for oxycodone hydrochloride's-controlled release rather than its instant distribution for chemotherapy patients' pain management will support the segment's growth.
Hospital Pharmacy Segment To Witness Growth At A Rapid Rate
The hospital pharmacy industry uses bulk oxycodone hydrochloride because hospitals play an important role in helping patients with a variety of pain-related disorders, including cancer, recovery from surgical procedures, and persistent diseases. As a result, there is an immense need for oxycodone pills in hospital settings, where doctors frequently provide them to treat severe and persistent pain. Furthermore, oxycodone's strict regulation and restricted nature call for careful surveillance and supervision, which are easily accessible in a hospital-controlled setting.
In The Region, The North American Oxycodone Hydrochloride Market Holds A Significant Revenue Share
The North American oxycodone hydrochloride market is predicted to record the highest market revenue share in the near future. This can be attributed to the widespread use of cutting-edge healthcare technologies and systems. Concerns about infectious diseases in the elderly and cost-effective detection are other factors driving demand for the product, and these factors are expected to persist throughout the forecast duration. In addition, Europe is projected to grow very fast in the global oxycodone hydrochloride industry because of the growth of a more advanced medical system and an upsurge in the regular individual's financial resources. Additionally, the market is expanding more quickly due to rising awareness of customized medications and the creation of oxycodone hydrochloride startups.
Recent Developments:
- In Oct 2024, Protega Pharmaceuticals stated that the FDA has approved oxycodone hydrochloride (RoxyBond) as an alternate therapy for the management of severe pain. Approval has been given for the administration of an immediate-release (IR) schedule II tablet at a dosage of 10 mg.
Oxycodone Hydrochloride Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 412.4 Mn |
|
Revenue Forecast In 2031 |
USD 572.8 Mn |
|
Growth Rate CAGR |
CAGR of 4.33% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Type, Route Of Administration, And Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Eli Lilly and Company, Gilead Sciences, Inc., Manus Aktteva Biopharma LLP, Arevipharma GmbH, Saneca Pharma a.s., Cipla Ltd., Noramco, Inc., MacFarlan Smith, Teva Pharmaceutical Industries Ltd., Taj Pharma, Chattem Chemicals Inc, Mayne Pharma Group Ltd., Dr. Reddy’s Laboratories Limited, Siegfried, Rhodes Pharmaceuticals L.P., Mallinckrodt Pharmaceuticals, Johnson & Johnson, Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Limited, Lupin Limited, and Sanofi S.A. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
